Clinical Trials Logo

Myeloid Malignancies clinical trials

View clinical trials related to Myeloid Malignancies.

Filter by:

NCT ID: NCT01731951 Completed - Clinical trials for Primary Myelofibrosis

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Start date: October 29, 2012
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies how well imetelstat sodium works in treating participants with primary or secondary myelofibrosis and other myeloid malignancies. Imetelstat sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01366612 Terminated - Clinical trials for Myelodysplastic Syndrome

PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation

FLUBUTBI
Start date: June 16, 2010
Phase: Phase 3
Study type: Interventional

This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation. A study population of 80 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible to receive allogeneic hematopoietic stem cell transplantation according to the eligibility criteria will be consented and enrolled. Subjects will be randomly assigned to receive one of 2 conditioning regimen: fludarabine and busulfan, or fludarabine busulfan and low dose total body irradiation (TBI). Subjects will be followed until 1 year post transplantation to assess the relapse rate in each arm and transplant-related toxicity. The combination of fludarabine and busulfan is the current standard of care for patients with myeloid malignancies (AML, CML and other myeloproliferative disorders, or MDS) undergoing allogeneic transplantation at HUMC. In this study we will be comparing in a randomized fashion the standard regimen to a regimen of fludarabine, busulfan and TBI.